Expanding the Role of Heparin Derivatives in Oncology: From Anticoagulation to Antitumor Activity DOI Creative Commons
Jasmine Holail, Hatouf H. Sukkarieh, Ahmad Aljada

и другие.

Pharmaceuticals, Год журнала: 2025, Номер 18(3), С. 396 - 396

Опубликована: Март 12, 2025

Current research demonstrates the expanding therapeutic potential of heparin derivatives in oncology, extending beyond traditional anticoagulation mechanisms. This systematic analysis examines structural characteristics, molecular mechanisms, and applications heparin-based compounds malignancy treatment. The essential antithrombin binding pentasaccharide sequence has enabled development specialized variants, particularly fractionated heparins their non-anticoagulant counterparts. These agents exert antineoplastic effects via multiple pathways, through modulation heparanase enzymatic activity specific protein–glycosaminoglycan interactions. Evidence from pivotal clinical trials (FRAGMATIC, MAGNOLIA, GASTRANOX) confirms efficacy managing cancer-associated thrombosis while indicating enhancement chemotherapeutic outcomes. preparation methods utilize cleavage reactions selective chemical derivatization to generate structurally modified exhibiting unique characteristics biological activities. Analysis glycosaminoglycan analog dociparstat sodium reveals significant myeloid malignancies, mediated by interference with CXCL12/CXCR4 signaling cascades. Significant challenges remain manufacturing scale-up, analytical validation, long-term safety assessment. Future studies must address dose optimization, combination strategies, controlled determine full these oncology.

Язык: Английский

Expanding the Role of Heparin Derivatives in Oncology: From Anticoagulation to Antitumor Activity DOI Creative Commons
Jasmine Holail, Hatouf H. Sukkarieh, Ahmad Aljada

и другие.

Pharmaceuticals, Год журнала: 2025, Номер 18(3), С. 396 - 396

Опубликована: Март 12, 2025

Current research demonstrates the expanding therapeutic potential of heparin derivatives in oncology, extending beyond traditional anticoagulation mechanisms. This systematic analysis examines structural characteristics, molecular mechanisms, and applications heparin-based compounds malignancy treatment. The essential antithrombin binding pentasaccharide sequence has enabled development specialized variants, particularly fractionated heparins their non-anticoagulant counterparts. These agents exert antineoplastic effects via multiple pathways, through modulation heparanase enzymatic activity specific protein–glycosaminoglycan interactions. Evidence from pivotal clinical trials (FRAGMATIC, MAGNOLIA, GASTRANOX) confirms efficacy managing cancer-associated thrombosis while indicating enhancement chemotherapeutic outcomes. preparation methods utilize cleavage reactions selective chemical derivatization to generate structurally modified exhibiting unique characteristics biological activities. Analysis glycosaminoglycan analog dociparstat sodium reveals significant myeloid malignancies, mediated by interference with CXCL12/CXCR4 signaling cascades. Significant challenges remain manufacturing scale-up, analytical validation, long-term safety assessment. Future studies must address dose optimization, combination strategies, controlled determine full these oncology.

Язык: Английский

Процитировано

0